- The DMC performed its first analysis on all cases, split between vaccinated individuals and those who received the placebo.
 indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. 
- 2-dose schedule 

Methods of Pfizer BNT162b1 First Interim from Phase 3 Study

- 7 days after the seconds dose, 90% efficacy was reported 
- 28 days after the initial dose, protection is achieved
- No reports of severe adverse events 

Results of Pfizer BNT162b1 First Interim from Phase 3 Study

At 90% efficacy with no serious adverse effects, this vaccine shows promise to effective for widespread protection. At the time of writing, Pfizer and BioNTech continue to enroll participants and acruse safety data

Conclusion of Pfizer BNT162b1 First Interim from Phase 3 Study

Smith College

BNT162b1 is a lipid nanoparticle–encapsulated, nucleoside-modified mRNA vaccine candidate from Pfizer/BioNTech against SARS-CoV-2, administered by intramuscular injection. Its mRNA encodes the spike glycoprotein's receptor-binding domain (RBD), which is trimerized via an added phage T4 fibritin–derived trimerization domain to raise immunogenicity; incorporating 1-methylpseudouridine increases translation efficiency while still engaging the innate immune response. Because the mRNA does not integrate into the host genome and is only transiently translated to produce the spike antigen that triggers immunity, the platform is considered relatively safe. In the phase 1/2 trials, healthy adults aged 18–55 received the vaccine at 10, 30, or 100 µg or placebo; IgG binding and spike neutralization were dose-dependent. About 7 days after vaccination, both vaccine and placebo recipients reported mild-to-moderate fatigue and headache—more frequently among vaccine recipients—with no fatal events observed. Safety follow-up continues for up to ~6 months and immunogenicity for up to 2 years, and adults over 65 have begun enrolling.

Pfizer BNT162b1

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study | Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against. Accessed 20 Nov. 2020.

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in FIrst Interim Analysis form Phase 3 Study

Mulligan, M., Lyke, K., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., . . . Jansen, K. (2020, January 01). Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. Retrieved August 05, 2020, from https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Learn Before

Related

Learn After